UK +44 (0) 203 929 0534 | US +1 (917) 297-6587

Development & Positioning Strategy

Which indications should we prioritise for follow-on Phase 3 clinical programs?

Eradigm was tasked with evaluating the opportunity for a new drug across five potential orphan indications, which spanned from rare nephrology to dermatology conditions.

We quantified the opportunity scientifically, clinically and commercially across all indications to provide a clear business case for prioritisation. This enabled our client to establish strategic launch sequence to maximise the lifetime revenues of their drug.

< Previous Case Study

Next Case Study >

Home                  Expertise                   Our Team                   Join us                    Contact us

Brand & Website design by GeoMedia           Privacy Policy

© 2019 Eradigm Limited, Registered England & Wales, No. 10491826
New Derwent House, 69-73 Theobalds Road, London, WC1X 8TA

Home                  Expertise                   Our Team                   Join Us                    Contact Us

Home                  Expertise                   Our Team
Join Us                    Contact Us

© 2019 Eradigm Limited, Registered England & Wales, No. 10491826
New Derwent House, 69-73 Theobalds Road, London, WC1X 8TA

© 2019 Eradigm Limited, Registered England & Wales, No. 10491826
New Derwent House, 69-73 Theobalds Road, London, WC1X 8TA

Brand & Website design by GeoMedia          Privacy Policy